Carboplatin · Kyxata, Paraplatin

What is Carboplatin?

Carboplatin is a platinum-based drug that binds to DNA and forms DNA cross-links, which inhibit DNA replication and transcription and trigger cytotoxic processes leading to cell death. It is studied in solid tumors including non-small cell lung cancer, head and neck cancer, melanoma, gastric cancer, renal cell carcinoma, and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Kyxata, Paraplatin, NSC-201345, NSC-241240

Drug type

Small molecule

Targets

DNA

Mechanism

Cytotoxic, directed at DNA

Pathways

DNA replication inhibition, DNA transcription inhibition, cytotoxic processes leading to cell death

Therapy area

Oncology

Developer

Corden Pharma

In trials of

CGEM, INBX

FDA status

Approved as Kyxata, Paraplatin (March 3, 1989), NDA019880 · FDA label

UNII

BG3F62OND5

✅ FDA-approved uses

• Ovarian carcinoma (Kyxata)

From the indications section of the FDA label (version of Sep 2, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorGastric CancerHead and Neck CancerMelanomaNon-Small Cell Lung CancerNSCLCRenal Cell CarcinomaResectable Non-Small-Cell Lung CancerSolid TumorUrothelial Carcinoma

Sources

• FDA label (DailyMed)
• FDA label Kyxata (2025-09-02), indications
• ClinicalTrials.gov NCT04198766
• ClinicalTrials.gov NCT04198766

Updated Oct 11, 2026.